Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I.

ABSTRACT:

Objective

Beta-2-glycoprotein I (β2 GPI) constitutes the major autoantigen in the antiphospholipid syndrome (APS), a common acquired cause of arterial and venous thrombosis. We recently described the novel observation that β2 GPI may exist in healthy individuals in a free thiol (biochemically reduced) form. The present study was undertaken to quantify the levels of total, reduced, and posttranslationally modified oxidized β2 GPI in APS patients compared to various control groups.

Methods

In a retrospective multicenter analysis, the proportion of β2 GPI with free thiols in serum from healthy volunteers was quantified. Assays for measurement of reduced as well as total circulating β2 GPI were developed and tested in the following groups: APS (with thrombosis) (n=139), autoimmu

SUBMITTER: Ioannou Y 

PROVIDER: S-EPMC3328749 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature